About c-Met

Patients with c-Met protein overexpressed NSCLC may have a worse prognosis than patients without c-Met protein overexpressed NSCLC7,8

An icon of 4 silhouettes of people, three in dark color and one highlighted in white

Prevalent

Approximately 1 in 8 patients with EGFR wt NSq NSCLC has high c-Met protein overexpression2*

 Icon of human lungs with branching airways

Poor prognosis

  • c-Met protein overexpression contributes to tumor growth and metastasis in NSq NSCLC9
  • Patients with c-Met protein overexpressed NSCLC may have a worse prognosis than patients without c-Met protein overexpressed NSCLC7,8
Icon of human lungs

c-Met protein expression has been shown to remain consistent throughout the advanced/metastatic NSCLC disease course10

Icon of a microscope displayed within a circular blue background
  • Testing can be performed at diagnosis or thereafter (with archived tissue or re-biopsy)2‡
  • You can test existing patients with archived tissue samples2‡

Biomarker testing is an important first step to inform treatment planning in NSCLC

A bar chart showing select biomarkers in NSCLC

The prevalence of selected actionable biomarkers does not indicate relative efficacy or safety of associated therapies. Some biomarkers may have greater characterization across various patient populations. Biomarker prevalence estimates are based on multiple sources. Prevalence data can vary among studies and data sets because of detection methodology used and patient sample sizes and/or demographic/characteristics. Some patients may have more than 1 NSCLC biomarker.

*High c-Met protein overexpression is defined as ≥50% of tumor cells with strong (3+) staining.1

Prevalence of 13.5% from the multicenter, open-label, non-randomized, single-arm, multi-cohort phase 2 LUMINOSITY clinical trial in patients with locally advanced or metastatic EGFR wt NSq NSCLC with high c-Met protein overexpression who received prior systemic therapy.1,2

Screening samples for patients enrolled in LUMINOSITY were collected from diagnosis through post-progression.2

EGFR=epidermal growth factor receptor; PD-L1=programmed death-ligand 1; TC=tumor cell; wt=wild type.